Abstract
Cancer is a consequence of mutations in genes that control cell proliferation, differentiation and cellular homeostasis. These genes are classified into two categories: oncogenes and tumor suppressor genes. Together, overexpression of oncogenes and loss of tumor suppressors are the dominant driving forces for tumorigenesis. Hence, targeting oncogenes and tumor suppressors hold tremendous therapeutic potential for cancer treatment. In the last decade, the predominant cancer drug discovery strategy has relied on a traditional reductionist approach of dissecting molecular signaling pathways and designing inhibitors for the selected oncogenic targets. Remarkable therapies have been developed using this approach; however, targeting oncogenes is only part of the picture. Our understanding of the importance of tumor suppressors in preventing tumorigenesis has also advanced significantly and provides a new therapeutic window of opportunity. Given that tumor suppressors are frequently mutated, deleted, or silenced with loss-of-function, restoring their normal functions to treat cancer holds tremendous therapeutic potential. With the rapid expansion in our knowledge of cancer over the last several decades, developing effective anticancer regimens against tumor suppressor pathways has never been more promising. In this article, we will review the concept of tumor suppression, and outline the major therapeutic strategies and challenges of targeting tumor suppressor networks for cancer therapeutics.
Keywords: RB, p53, BRCA1, BRCA2, gene therapy, small molecule inhibitors, tumor suppressors.
Current Drug Targets
Title:Targeting Tumor Suppressor Networks for Cancer Therapeutics
Volume: 15 Issue: 1
Author(s): Xuning Emily Guo, Bryan Ngo, Aram Sandaldjian Modrek and Wen-Hwa Lee
Affiliation:
Keywords: RB, p53, BRCA1, BRCA2, gene therapy, small molecule inhibitors, tumor suppressors.
Abstract: Cancer is a consequence of mutations in genes that control cell proliferation, differentiation and cellular homeostasis. These genes are classified into two categories: oncogenes and tumor suppressor genes. Together, overexpression of oncogenes and loss of tumor suppressors are the dominant driving forces for tumorigenesis. Hence, targeting oncogenes and tumor suppressors hold tremendous therapeutic potential for cancer treatment. In the last decade, the predominant cancer drug discovery strategy has relied on a traditional reductionist approach of dissecting molecular signaling pathways and designing inhibitors for the selected oncogenic targets. Remarkable therapies have been developed using this approach; however, targeting oncogenes is only part of the picture. Our understanding of the importance of tumor suppressors in preventing tumorigenesis has also advanced significantly and provides a new therapeutic window of opportunity. Given that tumor suppressors are frequently mutated, deleted, or silenced with loss-of-function, restoring their normal functions to treat cancer holds tremendous therapeutic potential. With the rapid expansion in our knowledge of cancer over the last several decades, developing effective anticancer regimens against tumor suppressor pathways has never been more promising. In this article, we will review the concept of tumor suppression, and outline the major therapeutic strategies and challenges of targeting tumor suppressor networks for cancer therapeutics.
Export Options
About this article
Cite this article as:
Guo Emily Xuning, Ngo Bryan, Modrek Sandaldjian Aram and Lee Wen-Hwa, Targeting Tumor Suppressor Networks for Cancer Therapeutics, Current Drug Targets 2014; 15 (1) . https://dx.doi.org/10.2174/1389450114666140106095151
DOI https://dx.doi.org/10.2174/1389450114666140106095151 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Impact of Proteomics in the Understanding of the Molecular Basis of Paclitaxel-Resistance in Ovarian Tumors
Current Cancer Drug Targets Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology The Position of Endoscopic Procedures in the Treatment of Obesity
Current Clinical Pharmacology Magnetic Resonance Elastography
Current Medical Imaging Patent Selections :
Recent Patents on Biomarkers DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
Current Drug Targets Current Strategies for the Treatment of Ulcerative Colitis
Recent Patents on Inflammation & Allergy Drug Discovery ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
Current Medicinal Chemistry Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Production of Active MMP7 in E. coli and Its Application for Metalloproteinase Inhibitors Screening
Protein & Peptide Letters Stimuli-responsive Carriers for Controlled Intracellular Drug Release
Current Medicinal Chemistry A Review on Onychine and its Analogs: Synthesis and Biological Activity
Current Organic Synthesis Potential Approaches to Enhance the Effects of Estrogen on Senescent Blood Vessels and Postmenopausal Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets Immunosuppressive Drugs in HIV Disease
Current Topics in Medicinal Chemistry Generation of Bispecific Antibodies by Fc Heterodimerization and their Application
Current Pharmaceutical Biotechnology N-substituted Pyrrole-based Scaffolds as Potential Anticancer and Antiviral Lead Structures
Medicinal Chemistry Spirulina paltensis: Food and Function
Current Nutrition & Food Science Proteasome Inhibitors in Cancer Therapy
Current Drug Targets